Perceive Biotherapeutics

Perceive Biotherapeutics is a private, preclinical-stage biotech founded in 2021 and based in Cambridge, Massachusetts. The company is built upon exclusive access to foundational research on two of the strongest protective biological pathways in retinal degeneration. Led by a seasoned team with extensive experience in ophthalmology and drug development, Perceive Bio is advancing a diversified pipeline aimed at halting vision loss in conditions like dry AMD. The company is currently preparing its lead programs for clinical entry.

A proprietary platform based on exclusive access to deep genetic insights and decades of academic research elucidating two of the strongest protective biological pathways in retinal degeneration. The company employs multiple therapeutic modalities to drug these validated targets.

Perceive Bio operates in the highly competitive retinal disease space, facing large pharmaceutical companies (e.g., Roche/Genentech, Apellis, Iveric Bio/Astellas) and numerous biotechs targeting dry AMD via complement inhibition, neuroprotection, gene therapy, and other modalities. Differentiation relies on its novel protective targets and genetic validation.